Genmab A/S
GMAB
$20.25
$0.050.25%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.12B | 2.89B | 2.76B | 2.59B | 2.39B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.12B | 2.89B | 2.76B | 2.59B | 2.39B |
| Cost of Revenue | 142.74M | 112.77M | 84.08M | 59.73M | 32.80M |
| Gross Profit | 2.98B | 2.77B | 2.67B | 2.53B | 2.36B |
| SG&A Expenses | 559.74M | 516.08M | 514.21M | 506.05M | 478.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.10B | 1.94B | 1.88B | 1.76B | 1.62B |
| Operating Income | 1.01B | 943.69M | 877.52M | 829.98M | 773.43M |
| Income Before Tax | 1.32B | 955.45M | 1.09B | 1.03B | 821.14M |
| Income Tax Expenses | 192.70M | 271.32M | 287.22M | 235.93M | 187.07M |
| Earnings from Continuing Operations | 1.13K | 684.13 | 804.84 | 796.74 | 634.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.13B | 684.13M | 804.84M | 796.74M | 634.07M |
| EBIT | 1.01B | 943.69M | 877.52M | 829.98M | 773.43M |
| EBITDA | 1.06B | 980.25M | 910.75M | 861.15M | 803.65M |
| EPS Basic | 17.70 | 10.60 | 12.37 | 12.20 | 9.71 |
| Normalized Basic EPS | 12.99 | 8.98 | 10.35 | 9.55 | 7.45 |
| EPS Diluted | 17.55 | 10.52 | 12.27 | 12.10 | 9.62 |
| Normalized Diluted EPS | 12.89 | 8.92 | 10.27 | 9.48 | 7.39 |
| Average Basic Shares Outstanding | 256.76M | 258.57M | 260.38M | 261.19M | 261.31M |
| Average Diluted Shares Outstanding | 258.60M | 260.51M | 262.48M | 263.42M | 263.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
